• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 20-F/A filed by Psyence Biomedical Ltd.

    7/25/25 4:12:06 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBM alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 20-F/A

    (Amendment No. 1)

     

    (Mark One)

     

    ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended March 31, 2025

     

    OR

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of event requiring this shell company report:

     

    Commission File Number: 001-41937

     

    Psyence Biomedical Ltd.

    (Exact name of Registrant as specified in its charter)

     

    Not applicable   Ontario, Canada
    (Translation of Registrant’s
    name into English)
      (Jurisdiction of incorporation
    or organization)

     

    121 Richmond Street West

    Penthouse Suite 1300

    Toronto, Ontario M5H 2K1

    +1 (416) 346-7764

    (Address of principal executive offices)

     

    Copy to:

    Neil Maresky

    121 Richmond Street West

    Penthouse Suite 1300

    Toronto, Ontario M5H 2K1

    +1 (416) 346-7764

    (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Common shares, without par value   PBM   The Nasdaq Stock Market LLC
    Warrants, each exercisable to
    purchase one Common Share at an
    exercise price of $6,874.13 per share
      PBMWW   The Nasdaq Stock Market LLC

     

    Securities registered or to be registered pursuant to Section 12(g) of the Act: None

     

    Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

     

     

     

    The number of the issuer’s outstanding common shares as of March 31, 2025 was 568,021 common shares. 

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐   No ☒

     

    If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐   No ☒

     

    Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒   No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or an emerging growth company. See definition of “accelerated filer,” “large accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒
            Emerging growth company ☒

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

     

    U.S. GAAP ☐ International Financial Reporting Standards as issue by the International Accounting Standards Board ☒ Other ☐

     

    If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

     

    If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

     

     

     

     

     

    Except as otherwise indicated or required by context, references in this Annual Report on Form 20-F (the “Report”) to “we,” “us,” “our,” “Psyence Biomedical” or the “Company” refer to Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada.

     

    Explanatory Note

     

    This Amendment No. 1 to the Annual Report on Form 20-F of Psyence Biomedical Ltd. for the fiscal year ended March 31, 2025 (the “Form 20-F”), originally filed with the Securities and Exchange Commission on June 25, 2025 (the “Original Filing”), is being filed solely to include management’s report on internal control over financial reporting under Item 15(b) that was inadvertently omitted from the Original Filing.

     

    This Amendment also includes re-executed certifications required under Section 302 of the Sarbanes-Oxley Act of 2002 as Exhibits 12.1 and 12.2, dated as of the date of this filing.

     

    This amendment does not reflect events occurring after the date of the Original Filing and does not update or otherwise modify any other disclosures made in the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing.

     

     

     

    ITEM 15. CONTROLS AND PROCEDURES

     

    Disclosure Controls and Procedures

     

    At the end of the period covered by this Report, an evaluation of the effectiveness of the design and operation of the Company’s “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) was carried out by the Company’s principal executive officer (the “CEO”) and principal financial officer (the “CFO”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon their evaluation, the Company’s CEO and CFO have concluded that, as of the end of the period covered by this Report, the design and operation of the Company’s disclosure controls and procedures were effective.

     

    Changes in Internal Control over Financial Reporting

     

    There has been no change in the Company’s internal control over financial reporting during the fiscal year ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting.

     

    Management’s Annual Report on Internal Control over Financial Reporting.

     

    Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

     

    Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

     

    Under the supervision and with the participation of our management, including our principal executive and principal financial officers, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2025. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of March 31, 2025.

     

    Attestation Report of the Registered Public Accounting Firm.

     

    This Report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting, as the Company is not required to obtain such an attestation pursuant to the rules of the Securities and Exchange Commission applicable to non-accelerated filers.

      

    ITEM 19. EXHIBITS

     

    Exhibit No.   Description
    12.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    12.2*   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    101.INS*   Inline XBRL Instance Document.
    101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
    101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
    101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
    104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 

     

    * Filed herewith.

     

    1

     

     

    SIGNATURE

     

    The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this report on its behalf.

     

    Dated: July 25, 2025 PSYENCE BIOMEDICAL LTD.
         
      By: /s/ Neil Maresky
      Name: Neil Maresky
      Title: Chief Executive Officer

     

    2

    0001985062 true FY 0001985062 2024-04-01 2025-03-31 0001985062 dei:BusinessContactMember 2024-04-01 2025-03-31 0001985062 pbm:CommonSharesWithoutParValueMember 2024-04-01 2025-03-31 0001985062 pbm:WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf1150PerShareMember 2024-04-01 2025-03-31 0001985062 2025-03-31 xbrli:shares
    Get the next $PBM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBM
    SEC Filings

    View All

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    9/5/25 4:05:13 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    8/28/25 4:05:03 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3 filed by Psyence Biomedical Ltd.

    F-3 - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    8/6/25 8:29:40 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

    NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025. The event, held at the Lotte New York Palace Hotel in New York City and virtually, features more than 550 corporate presentations from leading growth companies across healthcare, technology, and finance. Dr. Neil Maresky, CEO of Psyence BioMed, will provide an overview of the Company's business strategy and pipeline.

    8/28/25 8:00:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Update, August 2025

    NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ:PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived psychedelic therapies for people living with serious mental health challenges. Over the past few months, Psyence BioMed (PBM) has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability. These developments reflect not only a shift in our momentum but also a broader evolution of the company – one I'm excited to share with you. Clinical Progress & Trial Expansion Psyence

    8/4/25 8:30:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLabs and continued that investment in 2025. This achievement reflects the impact of Psyence BioMed's ongoing investment and collaboration, which continues to support PsyLabs' development of

    7/31/25 7:30:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Leadership Updates

    Live Leadership Updates

    View All

    Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

    NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

    2/26/25 8:00:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

    NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 (the "Meeting"). Shareholders were represented in person or by proxy at the meeting holding 21,877,200 common shares, representing approximately 43.5% of Psyence Biomed's 50,334,170 issued and outstanding common shares as of October 10, 2024, the record date for the Meeting. At the Meeting, a total of five resolutions (the "Resolutions" and each a "Resolution") were submitted to and approved by the Company's shareholder

    11/12/24 4:30:00 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

    Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc ("Clairvoyant"), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings

    9/6/24 7:30:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care